PAVmed — Third Quarter 2026 Earnings Summary

PAVmed reported preliminary third-quarter 2026 financial results showing operating expenses of approximately $6.8 million and a non-GAAP adjusted net loss of $1.2 million. Its subsidiary Lucid Diagnostics began receiving Medicare payments for its EsoGuard test in October and recognized $1.2 million in revenue for the quarter. Veris Health achieved a design freeze for its implantable physiological monitor and initiated a 90-day GLP animal study ahead of an expected early 2027 FDA submission. Additionally, PAVmed engaged with the FDA regarding its PortIO and Octeris products, with Octeris preparing to submit an initial pre-submission package.